logo

A S U

Ain Shams Specialized Hospital Launches an Advanced Unit for Molecular Diagnostics of Tumors

In a significant advancement that strengthens Ain Shams University Hospitals' capabilities in precision medicine, Ain Shams Specialized Hospital has launched the Targeted Molecular Diagnostic Unit (ASUSH–TMDU) within the hospital's Pathology Unit. The launch took place under the patronage of Prof. Mohamed Diaa Zain El-Abedeen, President of Ain Shams University; Prof. Ali El-Anwar, Dean of the Faculty of Medicine and Chairman of the University Hospitals' Board of Directors; and Prof. Tarek Youssef, Executive Director of the University Hospitals. It was supervised by Prof. Hisham El-Anwar, Director of Ain Shams Specialized Hospital; Prof. Haitham Abdel Azim, Deputy Director of the Hospital; Prof. Mohamed Abdel Razek, Medical Director of the Hospital; Prof. Manal El-Mahdi, Head of the Pathology Department; and Prof. Nehal Radwan, Director of the Hospital's Pathology Unit. The new unit aims to provide advanced diagnostic services utilizing the latest international technologies to detect genetic alterations and mutations associated with tumors and support the selection of targeted therapies based on the molecular characteristics of each case.

         
   
         

This initiative comes as part of Ain Shams University's strategy to develop its healthcare system, improve the quality of medical and diagnostic services provided to patients, and promote the use of modern technologies to enhance diagnostic accuracy and the effectiveness of treatment decisions, in line with rapid advancements in precision medicine and oncology.

The launch of the unit reflects the growing transformation in cancer diagnosis and treatment. Diagnosis is no longer limited to identifying the type of tumor and its histological characteristics but now extends to analyzing associated genetic and molecular alterations, which play a fundamental role in determining the most appropriate treatment options for each patient.

The unit enables the detection of targeted genetic mutations and alterations and the identification of molecular biomarkers of therapeutic significance. This provides accurate information to help medical teams select targeted therapies and supports the implementation of personalized medicine, which involves tailoring treatment plans to the biological and molecular characteristics of each individual case.

         
   
         

The unit utilizes state-of-the-art Polymerase Chain Reaction (PCR) systems, providing an integrated platform for targeted molecular testing, enhancing operational efficiency, accuracy, and reliability of results while reducing the time required for analysis.

The unit's diagnostic services include detecting genetic mutations and alterations of diagnostic and therapeutic significance, identifying molecular biomarkers associated with the selection of targeted therapies, and providing essential molecular data to support medical decision-making in collaboration with treating medical teams. This strengthens integration between pathology and various clinical specialties.

As a significant competitive advantage, the unit can complete diagnostic tests and issue results within 3 to 5 days, depending on the type of test and the requirements of each case, while adhering to quality and accuracy standards in testing procedures and result evaluation. This helps reduce patient waiting times, accelerate treatment decisions, and support the timely initiation of appropriate therapy, compared with waiting periods that may reach two weeks at many other medical institutions.

   
   


Excellence certificate